22157.jpg
2023 Annual Next-Gen Immuno-Oncology Congress: Latest Updates in ADC's, mAb, BsAbs, Immune Checkpoint Inhibitors, and Cellular Therapy (Boston, MA, United States - June 22-23, 2023)
09 mars 2023 09h18 HE | Research and Markets
Dublin, March 09, 2023 (GLOBE NEWSWIRE) -- The "6th Annual Next-Gen Immuno-Oncology Conference" conference has been added to ResearchAndMarkets.com's offering. The 6th Annual Next Gen...
22157.jpg
Market Forecasts for Immuno-Oncology Diagnostics 2023: Outcome Potential and Companion Diagnostics Driving Growth
16 janv. 2023 07h58 HE | Research and Markets
Dublin, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2023 to 2027" report has...
22157.jpg
Global Immuno-Oncology Diagnostics Market Research Report 2023: Gain an Understanding of Growth Expectations and the Ultimate Potential Market Size
13 janv. 2023 04h53 HE | Research and Markets
Dublin, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates" report has been added to ResearchAndMarkets.com's...
22157.jpg
2022 Outlook on the Anti TIGIT Antibody Global Market: By Phase, Company, Country and Indication
05 déc. 2022 06h33 HE | Research and Markets
Dublin, Dec. 05, 2022 (GLOBE NEWSWIRE) -- The "Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023" report has been added to ResearchAndMarkets.com's offering. This report...
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15 nov. 2022 04h00 HE | AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors  - Potential as mono- and combination therapy for...
Picture1.jpg
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
08 nov. 2022 07h33 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), a developer of treatments for rare and orphan indications,...
22157.jpg
Global Immuno-Oncology Diagnostics Market Research Report 2022-2026: Diagnostics Plays New Key Role in Therapeutic Development and Clinical Trials
08 juin 2022 03h53 HE | Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics, Including Executive/Consultant Guides and Customized Forecasting/Analysis 2022 - 2026" report has...
AKOYA Bio - Logo - Standard Centered.png
Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022
06 avr. 2022 08h05 HE | Akoya Biosciences, Inc.
Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the tumor microenvironmentThe Company will also showcase its novel protein chemistry to accelerate...
22157.jpg
Global Immuno-Oncology Diagnostics Market Research Report 2022: Explosion in Immuno-Oncology Therapies Creates an Exploding Diagnostic Market - Forecast to 2027
29 mars 2022 04h13 HE | Research and Markets
Dublin, March 29, 2022 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates" report has been added to ResearchAndMarkets.com's offering....
22157.jpg
Proto Oncogene Protein C-MYC Inhibitors Industry 2021 Featuring Insights for 15+ Companies and Drugs, Including RRx-001 (EpicentRx) and WP1066 (Moleculin Biotech)
23 déc. 2021 05h28 HE | Research and Markets
Dublin, Dec. 23, 2021 (GLOBE NEWSWIRE) -- The "Proto Oncogene Protein C-MYC Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This report...